Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.54 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932337 | 0.87 | GABRA5 (0.51) | MAPTGABRA5LMNAHPGDS | |
| SCHEMBL13701799 | 0.84 | NNMT (0.58) | MAPTGABRA5CXCR1CXCR2LMNA | |
| SCHEMBL13701755 | 0.84 | L3MBTL1 (0.65) | MAPTGABRA5DGAT1 | |
| SCHEMBL1091622 | 0.83 | MAPT (0.68) | MAPTGABRA5CXCR1CXCR2 | |
| SCHEMBL6927923 | 0.82 | GABRA5 (0.63) | GABRA5CXCR1CXCR2 | |
| SCHEMBL13702389 | 0.81 | MAPT (0.66) | MAPTGABRA5DGAT1CXCR1CXCR2 | |
| SCHEMBL13875908 | 0.80 | MAPT (0.68) | MAPTDGAT1CXCR1CXCR2 | |
| SCHEMBL26153240 | 0.80 | LMNA (0.46) | MAPTGABRA5LMNAHPGDSHTT | |
| SCHEMBL13701718 | 0.78 | GRN (0.63) | GABRA5LMNAHPGDS | |
| SCHEMBL21394819 | 0.78 | MAPT (0.70) | MAPTGABRA5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | MAPT 4084/4885GABRA5 3805/4885DGAT1 1488/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | MAPT 302/4885GABRA5 383/4885DGAT1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.